CB2 receptor‐selective agonists as candidates for targeting infection, inflammation, and immunity in SARS‐CoV ‐2 infections-Reference-Cited by-同舟云学术

CB2 receptor‐selective agonists as candidates for targeting infection, inflammation, and immunity in SARS‐CoV ‐2 infections

Published:2020-11-15 Issue:1 Volume:82 Page:7-11
ISSN:0272-4391
Container-title:Drug Development Research
language:en
Short-container-title:Drug Dev Res

Author:

Meeran M. F.¹,Sharma Charu²,Goyal Sameer N.³,Kumar Sanjay⁴,Ojha Shreesh¹^ORCID

Affiliation:

1. Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences United Arab Emirates University P.O. Box ‐ 17666 Al Ain United Arab Emirates

2. Department of Internal Medicine, College of Medicine and Health Sciences United Arab Emirates University P.O. Box ‐ 17666 Al Ain United Arab Emirates

3. Shri Vile Parle Kelvani Mandal's Institute of Pharmacy Dhule Maharashtra 424 001 India

4. Division of Hematology Division of Nephrology, Mayo Clinic Rochester Minnesota USA

Publisher

Wiley

Subject

Drug Discovery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ddr.21752

Reference33 articles.

1. Current Status of COVID-19 Therapies and Drug Repositioning Applications

2. PPAR-γ Activation As an Anti-inflammatory Therapy for Respiratory Virus Infections

3. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression